Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
1005-28-1|n/a,n/a|1|105|none (controls)|0|unit code not relevant|Injection, intravenous|Citrate control|58 (0 in ERA)|Rodent Other|Hamsters, Chinese|Both|Young Adult|Lifespan, liver cancer and chromosome aberrations|No information on individuals available for this study
1005-28-2|n/a,n/a|1|105|none (controls)|0|unit code not relevant|Injection, intravenous|Dextrine control|51 (0 in ERA)|Rodent Other|Hamsters, Chinese|Both|Young Adult|Lifespan, liver cancer and chromosome aberrations|No information on individuals available for this study
1005-28-3|n/a,n/a|1|105|Pu-238 citrate|7.4|becquerels per g animal|Injection, intravenous|single injection|97 (0 in ERA)|Rodent Other|Hamsters, Chinese|Both|Young Adult|Lifespan, liver cancer and chromosome aberrations|No information on individuals available for this study
1005-28-4|n/a,n/a|1|105|Th-232 colloid (Thorotrast)|0.3|becquerels per g animal|Injection, intravenous|single injection|100 (0 in ERA)|Rodent Other|Hamsters, Chinese|Both|Young Adult|Lifespan, liver cancer and chromosome aberrations|No information on individuals available for this study
1005-28-5|n/a,n/a|1|105|Th-232 colloid (Thorotrast)|1.5|becquerels per g animal|Injection, intravenous|single injection|100 (0 in ERA)|Rodent Other|Hamsters, Chinese|Both|Young Adult|Lifespan, liver cancer and chromosome aberrations|No information on individuals available for this study
1005-28-6|n/a,n/a|1|105|Th-232 colloid (Thorotrast)|7.4|becquerels per g animal|Injection, intravenous|single injection|54 (0 in ERA)|Rodent Other|Hamsters, Chinese|Both|Young Adult|Lifespan, liver cancer and chromosome aberrations|No information on individuals available for this study
